[go: up one dir, main page]

WO2005023848A3 - Epitopes adenoviraux - Google Patents

Epitopes adenoviraux Download PDF

Info

Publication number
WO2005023848A3
WO2005023848A3 PCT/GB2004/003861 GB2004003861W WO2005023848A3 WO 2005023848 A3 WO2005023848 A3 WO 2005023848A3 GB 2004003861 W GB2004003861 W GB 2004003861W WO 2005023848 A3 WO2005023848 A3 WO 2005023848A3
Authority
WO
WIPO (PCT)
Prior art keywords
adenoviral
fragment
epitope
region
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2004/003861
Other languages
English (en)
Other versions
WO2005023848A2 (fr
Inventor
Niels Rudi Pedersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0321063A external-priority patent/GB0321063D0/en
Priority claimed from GB0321179A external-priority patent/GB0321179D0/en
Application filed by Individual filed Critical Individual
Priority to EP20040768408 priority Critical patent/EP1664099A2/fr
Publication of WO2005023848A2 publication Critical patent/WO2005023848A2/fr
Publication of WO2005023848A3 publication Critical patent/WO2005023848A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un peptide compreant un épitope à base de Penton adénoviral pour un humain neutralisant les anticorps ; ledit épitope peut être un fragment provenant de la région 50-120, 191-233 ou 310-408 d'adénovirus 5 ou une région équivalente à l'intérieur d'un autre sérotype d'adénovirus, ou un variant équivalent de manière immunologique dudit fragment. Les épitopes préférés comprennent GGRNSIRYSELA, TRVYLVDNKSTD, QTINLDDRSHWG, HYLKVGRQNGVL, FRLGFDPVTGLV, VTGLVMPGVYTN, SNSSGSGAEENS, DHAIRGDTFATR, DSTFTQYRSWYL, RRTCPYVYKALG. L'invention concerne également l'utilisation desdits peptides et des molécules d'acides nucléiques dans la thérapie et les formulations comprenant lesdites molécules, éventuellement associées à un vecteur adénoviral.
PCT/GB2004/003861 2003-09-09 2004-09-09 Epitopes adenoviraux Ceased WO2005023848A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP20040768408 EP1664099A2 (fr) 2003-09-09 2004-09-09 Epitopes adenoviraux

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0321063A GB0321063D0 (en) 2003-09-09 2003-09-09 Adenoviral epitopes
GB0321063.0 2003-09-09
GB0321179.4 2003-09-10
GB0321179A GB0321179D0 (en) 2003-09-10 2003-09-10 Adenoviral epitopes

Publications (2)

Publication Number Publication Date
WO2005023848A2 WO2005023848A2 (fr) 2005-03-17
WO2005023848A3 true WO2005023848A3 (fr) 2005-12-01

Family

ID=34276832

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/003861 Ceased WO2005023848A2 (fr) 2003-09-09 2004-09-09 Epitopes adenoviraux

Country Status (2)

Country Link
EP (1) EP1664099A2 (fr)
WO (1) WO2005023848A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014153204A1 (fr) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Compositions d'adénovirus oncolytiques
CL2016000164A1 (es) * 2016-01-21 2016-07-29 Pontificia Universidad Católica De Chile Anticuerpos monoclonales específicos para el antígeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por adv.
CA3013637A1 (fr) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Dosage a haut debit pour mesurer la cinetique de replication d'un adenovirus
AU2017223589B2 (en) 2016-02-23 2023-08-03 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
JP2019536468A (ja) 2016-12-12 2019-12-19 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍を標的にする合成アデノウイルスおよびその使用
MX2020010499A (es) 2018-04-09 2020-10-28 Salk Inst For Biological Studi Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion.
EP3715374A1 (fr) 2019-03-23 2020-09-30 Ablevia biotech GmbH Composé de séquestration d'anticorps indésirables chez un patient
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
US12440544B2 (en) 2019-09-04 2025-10-14 The Board Of Trustees Of The Leland Stanford Junior University Cross-reactive epitope for multiple sclerosis
MX2023003377A (es) 2020-09-23 2023-03-31 Ablevia Biotech Gmbh Compuesto para aumentar la eficacia de los vectores virales.
EP4499132A1 (fr) 2022-03-24 2025-02-05 Ablevia biotech GmbH Composé pour augmentation de l'efficacité des virus oncolytiques

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHROBOCZEK ET AL: "THE SEQUENCE OF THE GENOME OF ADENOVIRUS TYPE 5 AND ITS COMPARISON WITH THE GENOME OF ADENOVIRUS TYPE 2", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 186, 1992, pages 280 - 285, XP002126551, ISSN: 0042-6822 *
DATABASE EMBL [online] 22 April 1989 (1989-04-22), "Adenovirus type 5 IIIa protein, 3' end; penton base protein gene, complete cds; and VIII protein, 5' end.", XP002341884, retrieved from EBI Database accession no. M22141 *
GAHERY-SEGARD H ET AL: "Immune reponse to recombinant capsid proteins of adenovirus in humans: Antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 72, no. 3, March 1998 (1998-03-01), pages 2388 - 2397, XP002136355, ISSN: 0022-538X *
HABIB N ET AL: "Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma", CANCER GENE THERAPY 2002 UNITED STATES, vol. 9, no. 3, 2002, pages 254 - 259, XP002337621, ISSN: 0929-1903 *
HABIB NAGY A ET AL: "E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors", HUMAN GENE THERAPY, vol. 12, no. 3, 10 February 2001 (2001-02-10), pages 219 - 226, XP002337622, ISSN: 1043-0342 *
HONG SAW SEE ET AL: "Identification of adenovirus (Ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative Ad (Addl1520) for treatment of liver tumors.", JOURNAL OF VIROLOGY, vol. 77, no. 19, October 2003 (2003-10-01), pages 10366 - 10375, XP002341790, ISSN: 0022-538X *
NEUMANN R ET AL: "DETERMINATION OF THE NUCLEOTIDE SEQUENCE FOR THE PENTON-BASE GENE OF HUMAN ADENOVIRUS TYPE 5", GENE (AMSTERDAM), vol. 69, no. 1, 1988, pages 153 - 157, XP002341791, ISSN: 0378-1119 *
SAW SEE HONG ET AL: "IMMUNOREACTIVE DOMAINS AND INTEGRIN-BINDING MOTIFS IN ADENOVIRUS PENTON BASE CAPSOMER", VIRAL IMMUNOLOGY, MARY ANN LIEBERT, INC., NEW YORK, US, vol. 13, no. 3, 2000, pages 353 - 371, XP009041783, ISSN: 0882-8245 *

Also Published As

Publication number Publication date
EP1664099A2 (fr) 2006-06-07
WO2005023848A2 (fr) 2005-03-17

Similar Documents

Publication Publication Date Title
WO2009117656A3 (fr) Antigène incorporé dans la capside pour nouveau vaccin à adénovirus
WO2008140812A3 (fr) Compositions et procédés comprenant des antigènes klk3, psca ou folh1
WO2003033654A3 (fr) Proteines de liaison de ciblage direct
WO2002053703A3 (fr) Vecteurs aav2 et procedes
IL210378A0 (en) Tumor associated antigen, peptides thereof, and use of same as ati-tumor vaccines
WO2007106476A3 (fr) Compositions et procédés pour renforcer l'immunogénicité d'antigènes
WO2004074455A3 (fr) Variants de la region fc
WO2005047860A3 (fr) Anticorps a l'alpha-synucleine
WO2001085932A3 (fr) Polypeptides immunogeniques codes par des minigenes mage et leurs utilisations
WO2007067730A3 (fr) Anticorps monoclonaux humains contre la proteine tyrosine kinase 7 (ptk7) et procedes pour utiliser des anticorps anti-ptk7
AU2003295502A1 (en) Adenoviral vector vaccine
WO2008020335A3 (fr) Compositions immunogènes pour streptococcus agalactiae
WO2002029086A3 (fr) Sequences d'acide nucleique differentiellement exprimees dans un tissu cancereux
WO2005023848A3 (fr) Epitopes adenoviraux
WO2009142460A3 (fr) Corps synergique fusionné anticorps-peptide
WO2004093808A3 (fr) Nouveaux antigenes associes a une tumeur
WO2006028429A3 (fr) Peptide pour cibler l'antigene prostatique membranaire specifique
WO2006081007A3 (fr) Utilisation de flagelline en immunotherapie antitumorale
WO2005030793A3 (fr) Anticorps se liant aux cxcr3 humains
WO2008124646A3 (fr) Utilisation de protéines amyloïdes en tant qu'échafaudages pour des vaccins
EP4599845A3 (fr) Procédés de prédiction de l'utilité de modifications d'acides aminés spécifiques d'une maladie pour l'immunothérapie
WO2002098456A3 (fr) Antigenes et vecteurs utilises pour la vaccination
WO2002036627A3 (fr) Interferons, utilisations et compositions associees
WO2002102316A3 (fr) Histone-deacetylase et procedes d'utilisation correspondants
WO2006054096A3 (fr) Proteines bifonctionnelles solubles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004768408

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004768408

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004768408

Country of ref document: EP